- Home
- INCR vs COEP Comparison
INCR vs COEP Comparison
Compare INCR & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCR
- COEP
- Stock Information
- Founded
- INCR 1994
- COEP 2017
- Country
- INCR Israel
- COEP United States
- Employees
- INCR N/A
- COEP N/A
- Industry
- INCR Biotechnology: Pharmaceutical Preparations
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INCR Health Care
- COEP Health Care
- Exchange
- INCR Nasdaq
- COEP Nasdaq
- Market Cap
- INCR 83.5M
- COEP 86.0M
- IPO Year
- INCR N/A
- COEP N/A
- Fundamental
- Price
- INCR $1.57
- COEP $16.65
- Analyst Decision
- INCR
- COEP
- Analyst Count
- INCR 0
- COEP 0
- Target Price
- INCR N/A
- COEP N/A
- AVG Volume (30 Days)
- INCR 131.9K
- COEP 65.4K
- Earning Date
- INCR 08-28-2025
- COEP 11-12-2025
- Dividend Yield
- INCR N/A
- COEP N/A
- EPS Growth
- INCR N/A
- COEP N/A
- EPS
- INCR N/A
- COEP N/A
- Revenue
- INCR $65,575,323.00
- COEP $263,555.00
- Revenue This Year
- INCR $69.54
- COEP N/A
- Revenue Next Year
- INCR $41.75
- COEP N/A
- P/E Ratio
- INCR N/A
- COEP N/A
- Revenue Growth
- INCR N/A
- COEP N/A
- 52 Week Low
- INCR $1.17
- COEP $2.31
- 52 Week High
- INCR $1.87
- COEP $19.19
- Technical
- Relative Strength Index (RSI)
- INCR 57.02
- COEP 60.64
- Support Level
- INCR $1.40
- COEP $16.50
- Resistance Level
- INCR $1.65
- COEP $18.15
- Average True Range (ATR)
- INCR 0.06
- COEP 1.58
- MACD
- INCR 0.01
- COEP 0.02
- Stochastic Oscillator
- INCR 81.11
- COEP 65.84
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.